Strategic Positioning CooperGenomics operates within the CooperSurgical family as a leading provider of comprehensive reproductive genetic testing, offering PGT-A via PGTai, PGT-M, PGT-SR, and ERPeak endometrial receptivity testing, presenting opportunities to upsell integrated fertility and genetic testing solutions to clinics seeking end-to-end reproductive care.

Established Revenue Reported revenue in the range of 25 to 50 million dollars with a mid-sized employee base, indicating a scalable platform that can support mid-market to enterprise-level partnerships with fertility clinics, hospitals, and reference labs seeking reputable genetics providers.

Clinical Focus Specialization in reproductive genetics positions CooperGenomics to target fertility clinics and IVF centers expanding their genetic screening offerings, enabling cross-sell of adjacent services such as endometrial receptivity testing and expanded genetic panels.

Tech & Compliance Utilization of marketing and data tools (Sixsense, Marketo, OneTrust, DocuSign) suggests readiness for targeted outreach, data-driven segmentation, and compliant contract workflows, which can streamline enterprise-level collaborations and large-scale deployments.

Growth Opportunities Potential partnerships with clinics and labs seeking leading-edge PGT capabilities present a path to expand geographic reach and product adoption, leveraging the CooperSurgical brand to win multi-site contracts and recurring testing volumes.